- Home
- CHRS vs IPHA Comparison
CHRS vs IPHA Comparison
Compare CHRS & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- IPHA
- Stock Information
- Founded
- CHRS 2010
- IPHA 1999
- Country
- CHRS United States
- IPHA France
- Employees
- CHRS 235
- IPHA N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- CHRS Health Care
- IPHA Health Care
- Exchange
- CHRS Nasdaq
- IPHA Nasdaq
- Market Cap
- CHRS 134.4M
- IPHA 150.9M
- IPO Year
- CHRS 2014
- IPHA 2019
- Fundamental
- Price
- CHRS $1.16
- IPHA $1.95
- Analyst Decision
- CHRS Strong Buy
- IPHA Strong Buy
- Analyst Count
- CHRS 4
- IPHA 1
- Target Price
- CHRS $5.38
- IPHA $11.50
- AVG Volume (30 Days)
- CHRS 2.4M
- IPHA 50.9K
- Earning Date
- CHRS 03-12-2025
- IPHA 03-20-2025
- Dividend Yield
- CHRS N/A
- IPHA N/A
- EPS Growth
- CHRS N/A
- IPHA N/A
- EPS
- CHRS N/A
- IPHA N/A
- Revenue
- CHRS $304,340,000.00
- IPHA $36,202,722.00
- Revenue This Year
- CHRS $2.47
- IPHA N/A
- Revenue Next Year
- CHRS N/A
- IPHA $101.65
- P/E Ratio
- CHRS N/A
- IPHA N/A
- Revenue Growth
- CHRS 44.19
- IPHA N/A
- 52 Week Low
- CHRS $0.66
- IPHA $1.29
- 52 Week High
- CHRS $2.87
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- CHRS 38.01
- IPHA 56.50
- Support Level
- CHRS $1.03
- IPHA $1.72
- Resistance Level
- CHRS $1.39
- IPHA $1.92
- Average True Range (ATR)
- CHRS 0.14
- IPHA 0.11
- MACD
- CHRS -0.03
- IPHA 0.02
- Stochastic Oscillator
- CHRS 14.04
- IPHA 89.74
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.